Progyny, Inc.
Progyny, Inc.
Your view on PGNY
Overview
What the company does, where it operates, and who runs it.
About Progyny, Inc.
- Industry
- Medical - Healthcare Plans
- Sector
- Healthcare
- CEO
- Peter Anevski CPA
- Headquarters
- 1359 Broadway, New York City, NY, US
- Industry
- Medical - Healthcare Plans
- Sector
- Healthcare
- CEO
- Peter Anevski CPA
- Headquarters
- 1359 Broadway, New York City, NY, US
Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.
The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers.
The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Progyny, Inc., and the rating behind it. PGNY last traded at $27.35, 28.3× trailing earnings — the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Progyny, Inc.. Starting points for Progyny, Inc.: P/E 28.3, EPS $1.01, beta 0.99 — an Medical - Healthcare Plans name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Progyny, Inc.. Progyny, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Progyny, Inc.. Trailing twelve-month EPS for Progyny, Inc. stands at $1.01. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Progyny, Inc.. Progyny, Inc. has reported as a listed company since 2019. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Progyny, Inc. valued side by side against its closest peers. Progyny, Inc. is measured against Medical - Healthcare Plans peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Progyny, Inc., and how their positions are changing. At a $2.14B market value, institutional positions materially move Progyny, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Progyny, Inc. executives and directors. Shares of Progyny, Inc. have traded between $13.50 and $27.25 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Progyny, Inc.. Progyny, Inc. is a $2.14B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Progyny, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Progyny, Inc.. Coverage tracks Progyny, Inc. within Medical - Healthcare Plans (Healthcare). Press releases and market coverage, newest first.